Tagged News

Xaira Therapeutics Launches with Record $1 Billion Funding to Revolutionize AI-Driven Drug Discovery

a year ago

Xaira Therapeutics launched with $1 billion in funding from ARCH Venture Partners and other major investors, marking the largest initial commitment in ARCH's nearly 40-year history.
The company aims to leverage generative AI and foundational models from the University of Washington's Institute of Protein Design to create drugs that were previously impossible to develop.
Former Stanford president and Genentech CSO Marc Tessier-Lavigne leads the company as CEO, with investors expressing confidence despite his recent resignation from Stanford following research data manipulation allegations at his former lab.
The funding reflects growing industry investment in generative AI for drug discovery, with the technology showing potential to optimize every stage of pharmaceutical R&D from target discovery to commercialization.

2 years ago

CU Medicine research demonstrates that AI-assisted colonoscopy significantly improves adenoma detection rates by 40% among junior endoscopists with less than three years of experience.
The study involved 766 patients and 22 junior endoscopists-in-training, showing particularly impressive performance improvements among beginners, addressing a critical gap in endoscopic training.
Researchers have also developed AI-Endo, an innovative AI surgical platform that guides surgeons through endoscopic submucosal dissection (ESD) procedures for early-stage gastrointestinal cancer treatment.

2 years ago

Insilico Medicine's INS018_055 becomes the first drug with both AI-discovered target and AI-generated design to reach Phase II clinical trials for idiopathic pulmonary fibrosis treatment.
The drug development process took just 30 months from target discovery to Phase I trials, approximately half the time of traditional drug discovery methods.
IPF affects about 100,000 people in the U.S. and typically leads to death within 2-5 years if untreated, with current treatments only slowing disease progression.
The Phase II trial is a randomized, double-blind, placebo-controlled study over 12 weeks in China, with plans to expand to 60 subjects across 40 sites in the U.S. and China.

4 years ago

Tempus received FDA 510(k) clearance for its Tempus ECG-AF device, marking the first FDA clearance for an atrial fibrillation indication in the cardiovascular machine learning-based notification software category.
The AI-based algorithm uses electrocardiogram data to help identify patients who may be at increased risk of atrial fibrillation and flutter.
This regulatory milestone represents a significant advancement in AI-enabled cardiovascular risk assessment and precision medicine applications.
The clearance positions Tempus to expand its AI capabilities beyond oncology into cardiovascular disease detection and prevention.

9 years ago

Image Analysis Group (IAG) and Alimentiv announced a strategic partnership to integrate IAG's DYNAMIKA AI platform into Alimentiv's comprehensive gastroenterology clinical trial services.
The collaboration introduces AI-driven histology endpoints and quantitative image analysis capabilities to enhance mucosal healing assessment and inflammation severity measurement in GI trials.
Alimentiv brings 30+ years of GI trial experience across 60+ countries, while IAG contributes proven AI technology validated through 700+ clinical trials since 2007.
The partnership aims to provide deeper insights into histologic changes and drug response at the cellular level, potentially accelerating gastroenterology drug development timelines.

NCT03783026CompletedPhase 4

Amgen

Posted 2/6/2019